GLP-1 medications have been called "game-changers" for weight loss. And for many people, they are. But here's what often gets buried under the headlines: not everyone responds to these drugs.
Clinical trials and real-world data consistently show that a significant minority of patients—somewhere between 10-23%—don't lose clinically meaningful weight on semaglutide or tirzepatide. Understanding why could help identify better treatment paths.
What the Data Shows
The numbers on non-response vary depending on how you define it, but the pattern is consistent:
| Study/Source | Non-Responder Rate | Definition |
|---|---|---|
| Novo Nordisk trials (semaglutide) | Up to 23% | <5% body weight loss |
| Semaglutide trial analysis | ~14% | <5% body weight loss |
| Same trial | ~33% | <10% body weight loss |
| Clinical practice (PBS report) | 10-12% | Minimal to no response |
Notably, Novo Nordisk's latest trial showed that even giving people a higher semaglutide dose didn't decrease the proportion of non-responders. More drug doesn't solve the problem.
Why Some People Don't Respond
Researchers are actively investigating what differentiates responders from non-responders. Several factors appear to play a role:
1. Genetics
🧬 The Genetic Factor
While most obesity is "polygenic" (influenced by thousands of genetic variants), specific genes may predict GLP-1 response:
- Neurobeachin gene: Cleveland Clinic researchers found variations in this gene predict liraglutide response. People with certain variants were 50%+ more likely to not lose weight.
- Appetite phenotypes: Mayo Clinic research identified "hungry brain" vs. "hungry gut" phenotypes that respond differently to GLP-1s.
Scientists at the University of Copenhagen and other institutions are investigating how genetic variations affect the GLP-1 pathway, but we're still in early stages of understanding this.
2. Type 2 Diabetes
Why Diabetics May Lose Less Weight
People with type 2 diabetes consistently lose less weight on GLP-1s than those without diabetes. The reasons are physiological:
- In T2D, the body's ability to respond to GLP-1 and stimulate insulin secretion is already reduced
- Pre-existing metabolic dysfunction makes weight loss more difficult
- Longer-standing metabolic disease creates more "uphill battle"
3. Biological Phenotypes
Dr. Andres Acosta at Mayo Clinic has identified four distinct biological "phenotypes" of people with excess weight:
| Phenotype | Description | GLP-1 Response |
|---|---|---|
| "Hungry Brain" | Satiety signals don't register properly in the brain | Poor response to GLP-1s |
| "Hungry Gut" | Stomach empties too quickly, hunger returns fast | Better response to GLP-1s |
| "Emotional Eating" | Food used to cope with emotions | Variable |
| "Slow Metabolism" | Burn fewer calories at rest | Variable |
In unpublished research presented at medical conferences, people with the "hungry gut" phenotype lost an average of 8.8 kg on semaglutide, while other phenotypes lost only 4.5 kg.
4. Other Medical Conditions
Comorbidities That May Affect Response
- Early-onset severe obesity in childhood
- Endocrine disorders (hypothyroidism, PCOS, Cushing's)
- Developmental delays
- History of trauma
- Mental health conditions
5. Medication Interactions
Certain medications can promote weight gain or interfere with weight loss, potentially counteracting GLP-1 effects:
- Some antidepressants (mirtazapine, paroxetine, certain TCAs)
- Antipsychotics (olanzapine, clozapine, quetiapine)
- Beta-blockers
- Corticosteroids
- Insulin and sulfonylureas
6. Sex Differences
Men, on average, lose less weight on GLP-1s than women. The reasons aren't fully understood but may relate to hormonal differences and body composition.
It's Not Always the Drug
Before concluding you're a non-responder, consider other factors:
- Diet: The medication reduces appetite but doesn't change food choices
- Physical activity: Exercise habits affect results
- Sleep: Poor sleep disrupts hunger hormones
- Stress: Chronic stress elevates cortisol, promoting fat storage
- Adherence: Missing doses or inconsistent use affects outcomes
What to Do If You're Not Responding
1. Give It Time
Full effects may take 4-6 months. The titration period (gradually increasing doses) is designed to build up medication levels while minimizing side effects. Don't judge results until you've been at the target dose for several weeks.
2. Verify the Basics
Work with your provider to ensure:
- You're taking the medication correctly and consistently
- No interfering medications are counteracting effects
- No underlying conditions (thyroid, PCOS) are being missed
3. Optimize Lifestyle Factors
The medication works best alongside diet and exercise changes. A registered dietitian can help identify dietary patterns that may be limiting results.
4. Consider Alternative Medications
| Option | Why It Might Help |
|---|---|
| Switch to tirzepatide | Dual mechanism (GLP-1 + GIP) may work for some semaglutide non-responders |
| Different GLP-1 | Liraglutide (Saxenda) has different dosing and may work differently |
| Contrave | Different mechanism (bupropion/naltrexone); works on reward pathways |
| Combination approach | Adding metformin or other agents to GLP-1 |
5. Genetic Testing (Emerging)
Some companies are beginning to offer genetic testing to predict GLP-1 response. This is still early-stage, but may become more useful as research advances.
The Future: Precision Obesity Medicine
Researchers envision a future where patients can be matched to the obesity treatment most likely to work for them—based on their genetics, phenotype, and other factors.
- Cleveland Clinic is studying genetic predictors of GLP-1 response
- Mayo Clinic is developing phenotyping tools to match patients to treatments
- Multiple studies are investigating why blood sugar response is more consistent than weight loss response
Until we have better predictive tools, treatment often involves trial and error—trying different medications and approaches until finding what works for an individual patient.
GLP-1 medications don't work equally for everyone. Approximately 10-23% of patients lose less than 5% of their body weight—clinically considered minimal response.
Factors that may predict poor response:
- Genetic variations in appetite-regulating pathways
- Pre-existing type 2 diabetes
- "Hungry brain" phenotype (satiety signals don't register)
- Complex metabolic or psychosocial comorbidities
- Medications that promote weight gain
- Male sex (men lose less on average)
If you're not responding: Give it adequate time, verify basics, optimize lifestyle, and discuss alternative medications with your provider. Switching to tirzepatide or a different mechanism may help some non-responders.
Sources
- Healthline. "Ozempic: 5 Reasons People Don't Lose Weight on GLP-1 Drugs." April 2024.
- Scientific American. "The New Weight-Loss Drugs Don't Work for Everyone. Genetics May Explain Why." October 2025.
- Becker's Hospital Review. "Up to 15% of patients on weight loss drugs may be 'non-responders'." April 2024.
- PBS NewsHour. "As weight loss drug demand soars, physician outlines effectiveness and potential downsides." January 2025.
- Advisory Board. "Weight-loss drugs don't work for everyone. Here's why." 2023/2025.
- Mayo Clinic Diet. "Why Ozempic might not be working in your weight-loss journey." November 2024.
Explore Your Options
Compare GLP-1 providers offering different medications and support approaches.
Compare Providers →